Eisai
OTC:ESALYPharmaTokyo, Japan, Japan · Est. 1941 · 10,000 employees
Eisai is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines across neurology, oncology, and other therapeutic areas.
7
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
6
Indications↗
Distinct diseases across all programs
572
Clinical Trials↗
All sponsored trials (all statuses)
38
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
7 drugs in development
Approved1
Phase 25
Phase 12
By Therapeutic Area
top 3
Oncology
450%
Immunology
113%
Neurology
113%
R&D Momentum
59/100
Pipeline Velocity
15/100
Trial Completion Rate
89/100
Pipeline Concentration
34/100
Pipeline Freshness
54/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Active, not recruiting
An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy
Jul 9, 2026
Available
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
Jul 7, 2026
Recruiting
Post Marketing Surveillance of Jyseleca Tab. (Filgotinib Maleate) in Korean Subjects
Jul 3, 2026
Active, not recruiting
A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Jul 3, 2026
Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus
Jul 2, 2026
Recruiting
A Multicenter, Postmarketing Observational (Noninterventional) Study to Evaluate the Safety of Fycompa for Injection in Patients With Partial-Onset Seizures (Including Secondarily Generalized Seizures) (Age 4 Years or Older) or Primary Generalized Tonic- Clonic Seizures (Age 12 Years or Older)
Details
Company Info
Company Overview
$30.0B
Mkt Cap
$5.5B
Revenue
—
Cash
CEOHaruo Naito
Founded1941
Employees10,000
HQTokyo, Japan, Japan
ExchangeOTC:ESALY
Websiteeisai.com
LinkedInCompany Page
Therapeutic Focus
OtherNeurologyRespiratoryNephrologyPsychiatryGastroenterologyOncologyImmunologyCardiovascularMetabolic & EndocrineOphthalmologyMusculoskeletalInfectious DiseaseRare DiseaseDermatologyHematology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Neurology
Unknown / Other
Immunology
Neurology
Narcolepsy
E2086Phase 2
Oncology
Unknown / Other
Pediatric
Perampanel Oral SuspensionPhase 2
Perampanel TabletPhase 2
Regulatory
Regulatory Timeline
19901 event
FDADec 26
Hexalen — HEXALEN
Application NDA019926 (NDA)
19961 event
FDANov 25
Aricept — ARICEPT
Application NDA020690 (NDA)
20042 events
FDAOct 18
Aricept — ARICEPT ODT
Application NDA021720 (NDA)
FDAOct 18
Aricept — ARICEPT
Application NDA021719 (NDA)
20082 events
FDADec 12
Lusedra — LUSEDRA
Application NDA022244 (NDA)
FDANov 14
Banzel — BANZEL
Application NDA021911 (NDA)
20102 events
FDANov 15
Halaven — HALAVEN
Application NDA201532 (NDA)
FDAJul 23
Aricept — ARICEPT
Application NDA022568 (NDA)
20111 event
FDAMar 3
Banzel — BANZEL
Application NDA201367 (NDA)
20151 event
FDAFeb 13
Lenvima — LENVIMA
Application NDA206947 (NDA)
20201 event
FDAApr 7
Dayvigo — DAYVIGO
Application NDA212028 (NDA)
20221 event
FDAMar 11
Aricept — ADLARITY
Application NDA212304 (NDA)
20231 event
FDAJan 6
Leqembi — LEQEMBI
Application BLA761269 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)